Physician

Brian Lehpamer, M.D.

According to 2025 Medicare claims, Brian Lehpamer, M.D. (NPI: 1093957326) practices ophthalmology in the Raleigh-Cary, NC market, with the plurality of this provider's patient population coming from Johnston, NC. This provider's primary affiliated billing organization is RETINA ASSOCIATES, PLLC (NPI: 1760408397; TIN: 562043271) and primary practice location at 27520-5803.

Lehpamer's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 991 traditional Medicare patients, billed 33,266 HCPCS/CPT codes, and received $3,389,807 in Medicare payments. The top billing code was J0178 (Injection, aflibercept, 1 mg). Part D data shows 777 prescription claims across 194 beneficiaries totaling $25,771 in drug costs, led by Prednisolone Acetate (Prednisolone Acetate). Open Payments data shows 11 records totaling $396. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $160,419 to $3,389,807. Similarly, Part D prescription costs have risen steadily, from $2,196 to $25,771. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.7M$3.4M2015 Medicare payment: $160,419 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $883,031 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $1,578,589 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $2,004,996 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $2,364,696 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $2,756,059 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $2,985,986 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $2,921,397 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $2,939,303 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $3,389,807 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015133747$160,419
20164964,094$883,031
20177416,914$1,578,589
20188038,398$2,004,996
201986610,054$2,364,696
202089610,953$2,756,059
20211,05211,829$2,985,986
20221,08911,646$2,921,397
20231,07122,949$2,939,303
202499133,266$3,389,807

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$30K$60K2015 Drug cost: $2,196 (USD; Tot_Drug_Cst)2016 Drug cost: $7,094 (USD; Tot_Drug_Cst)2017 Drug cost: $10,729 (USD; Tot_Drug_Cst)2018 Drug cost: $13,711 (USD; Tot_Drug_Cst)2019 Drug cost: $22,414 (USD; Tot_Drug_Cst)2020 Drug cost: $43,921 (USD; Tot_Drug_Cst)2021 Drug cost: $59,606 (USD; Tot_Drug_Cst)2022 Drug cost: $49,542 (USD; Tot_Drug_Cst)2023 Drug cost: $38,308 (USD; Tot_Drug_Cst)2024 Drug cost: $25,771 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
20151763$2,196
201653152$7,094
2017114307$10,729
2018115320$13,711
2019136444$22,414
2020189692$43,921
2021245872$59,606
2022248869$49,542
2023216854$38,308
2024194777$25,771

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
J0178Injection, aflibercept, 1 mg2512,030$656
67028Injection of drug into eye4271,775$93
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more7211,066$62
92134Imaging of retina4271,169$28
92250Photography of the retina9011,512$26

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
Prednisolone AcetatePrednisolone Acetate1575,976$6,333
Ketorolac TromethamineKetorolac Tromethamine1395,447$3,644
Brimonidine TartrateBrimonidine Tartrate612,531$2,131
Dorzolamide HclDorzolamide Hcl935,756$2,017
LatanoprostLatanoprost875,047$1,053

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.11$396Regeneron Healthcare Solutions, Inc.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Brian Lehpamer, M.D.?

Tedicare shows public-source Medicare data for Brian Lehpamer, M.D. (NPI 1093957326), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Brian Lehpamer, M.D. have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Brian Lehpamer, M.D.?

Brian Lehpamer, M.D. is linked to RETINA ASSOCIATES, PLLC (billing NPI 1760408397) in the available physician profile data.

Does Brian Lehpamer, M.D. have Open Payments data?

Brian Lehpamer, M.D. has 11 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.